Published in Blood Weekly, September 1st, 2011
"With government agencies and medical societies focused on healthcare reform and infection reduction, we recognize that our rapid therapy adoption is an acknowledgement of the proven reduction in costly infections in both the hospital and clinical based settings. HeRO is quickly becoming a standard of care for catheter-dependent hemodialysis patients who have failed other access options due to venous outflow...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.